DeepCardio

PRODUCT

DeepCardio's research and development to predict the risk of all cardiac diseases using only an ECG test is ongoing.

Currently, 3 products are commercially available and 8 products have completed development and are undergoing pilot testing.

SmartECG Product Pipeline

SmartECG technology is an AI-based platform that uses a single ECG dataset to predict the likelihood of various cardiac conditions — including arrhythmia, heart failure, cardiovascular risk, and coronary artery disease.
It is expanding beyond anomaly detection to risk quantification and clinical decision support.

Product
In Development
Pilot Test
Regulatory Approval
Commercially Available
  • SmartECG-AF Risk
    On Market
  • SmartECG-CV Risk (Wellness)
    On Market
  • SmartECG-CV Risk (Medical Device)
    In Approval
  • SmartECG-EF
    On Market
  • SmartECG-sigCAD risk
    In Approval
  • SmartECG-ACS risk
    In Approval
  • SmartECG-HFmrEF
    Pilot Test
  • SmartECG-HCMP
    Pilot Test
  • SmartECG-Fabry
    Pilot Test

DeepCardio's SmartECG pipeline is expanding beyond atrial fibrillation, heart failure, and cardiovascular risk —
reaching coronary artery disease and rare cardiac conditions.
This represents the evolution toward an AI-powered,
full-cycle cardiac healthcare platform that sets a new standard in cardiac disease management.

Contact Us